NCT07543172 2026-04-21
CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer
Roswell Park Cancer Institute
Phase 2 Not yet recruiting
Clinical Trials
10 trialsNCT06497556 2026-04-20
Krascendo 1
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT07288034 2026-04-15
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT06026410 2026-04-14
FIT-001
Kura Oncology, Inc.
Phase 1 Recruiting
NCT03994796 2026-04-13
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT06130254 2026-04-09
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06248606 2026-04-08
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT07415031 2026-04-08
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Phase 2 Not yet recruiting
NCT06875310 2026-04-07
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.
Phase 3 Recruiting
NCT05853575 2026-03-27
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Mirati Therapeutics Inc.
Phase 2 Active not recruiting